



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NO.     | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---------------------|-------------|----------------------|---------------------|------------------|
| 10/566,863          | 03/27/2007  | Nureddin Ashammakhi  | 12808/30            | 2237             |
| 26646               | 7590        | 10/15/2009           | EXAMINER            |                  |
| KENYON & KENYON LLP |             |                      | XIE, XIAOZHEN       |                  |
| ONE BROADWAY        |             |                      |                     |                  |
| NEW YORK, NY 10004  |             |                      | ART UNIT            | PAPER NUMBER     |
|                     |             |                      | 1646                |                  |
|                     |             |                      | MAIL DATE           | DELIVERY MODE    |
|                     |             |                      | 10/15/2009          | PAPER            |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

|                              |                        |                     |  |
|------------------------------|------------------------|---------------------|--|
| <b>Office Action Summary</b> | <b>Application No.</b> | <b>Applicant(s)</b> |  |
|                              | 10/566,863             | ASHAMMAKHI ET AL.   |  |
|                              | <b>Examiner</b>        | <b>Art Unit</b>     |  |
|                              | XIAOZHEN XIE           | 1646                |  |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 31 January 2006.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) 1-21 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ .                                    |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ .  | 6) <input type="checkbox"/> Other: _____ .                        |

## DETAILED ACTION

### ***Election/Restrictions***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1, 2, 6-10, 12, 14, 18 and 21 are drawn to a multifunctional implant device for bone augmentation function, comprising: a biocompatible bioresorbable polymer as a matrix, an anti-osteolytic agent in the matrix, and a reinforcing structure in close association with the matrix; wherein the biocompatible bioresorbable polymer is self-reinforced.
- II. Claims 1, 3, 4, 6-10, 13, 15, 16 and 19-21 are drawn to a multifunctional implant device for bone augmentation function, comprising: a biocompatible bioresorbable polymer as a matrix, an anti-osteolytic agent in the matrix, and a reinforcing structure in close association with the matrix; wherein the implant device comprises discrete reinforcing elements or areas of the same bioresorbable polymer.
- III. Claims 1, 3, 5-11, 13, 15, 17, 19 and 21 are drawn to a multifunctional implant device for bone augmentation function, comprising: a biocompatible bioresorbable polymer as a matrix, an anti-osteolytic agent in the matrix, and a

reinforcing structure in close association with the matrix; wherein the implant device comprises discrete reinforcing elements or areas of different material.

The inventions listed as I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

According to PCT Rule 13.2, unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as Groups I-III do not relate to a single general inventive concept because they lack the same or corresponding technical feature. The technical feature of claim 1 is a multifunctional implant device for bone augmentation, comprising: a biocompatible bioresorbable polymer as a matrix, an anti-osteolytic agent in the matrix, and a reinforcing structure in close association with the matrix.

Schryver et al. (US 2003/0055511, Pub. Date: Mar. 20, 2003) teach a bone graft substitute (BGS) made of shaped particles and the use of BGS to repair, replace, augment or improve a bone deficiency [0002]. Schryver et al. teach that the material of the shaped particles could be derived from a variety of bioresorbable and biocompatible polymers, and the polymers allow control of mechanical properties, such as strength and stiffness [0142]. Schryver et al. teach that the particle comprises a biological agent, e.g., biophosphonate [0040]. Thus, Schryver et al. teach the limitations of claim 1, and therefore the technical feature of Group I lacks novelty or inventive step and does not make a contribution over the prior art.

Since the 1<sup>st</sup> claimed invention has no special technical feature, it cannot share a special technical feature with the other claimed inventions.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Xiaozhen Xie, Ph.D. whose telephone number is 571-272-5569. The examiner can normally be reached on M-F, 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary B. Nickol, Ph.D. can be reached 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Xiaozhen Xie/  
Xiaozhen Xie, Ph.D.  
September 14, 2009